Blogs

Latest Blogs

From Detection to Decision: Risk-Based Immunogenicity Testing

April 29, 2026

Immunogenicity describes treatment‑induced B‑ and T‑cell responses to therapeutics and represents a major hurdle for drug development, due to the potential impact on patient safety…

The Next Frontier for CAR T-Cell Therapy: Shifting Gears to Autoimmune Conditions

February 18, 2025

CAR T-cell therapy has transformed cancer treatment, offering new hope for patients with aggressive B cell malignancies like acute lymphoblastic…

Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials

October 18, 2024

Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…

Allogeneic CAR T cell therapies: A major step forward

October 9, 2024

In a groundbreaking clinical trial, three individuals suffering from severe autoimmune diseases have entered remission following a novel CAR T…

A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology

September 17, 2024

Are antibody-drug conjugates (ADCs), principally comprised of an antibody, a cytotoxic payload and a linker, the next therapeutic modality of…

The mpox outbreak: Variants, transmission and the boost for vaccine manufacturers

September 5, 2024

Following Covid-19, the world is collectively on high alert for anything that could indicate another pandemic. What do we know…

The STING in the tail: How our own defense mechanisms to infection may be working against us

August 29, 2024

In this latest blog, we explore this pathway, its burgeoning links to multiple diseases and how biomarker profiling can assist…